Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MT2004 in Cholestatic and Mixed Drug Induced Liver Injury
NCT06019936Phase 2Recruiting
- Sponsor
- Xi'an Aolitai Pharmaceutical Technology
- Start
- Aug 2023
- Primary completion
- Aug 2025
- Modality
- Prodrugs/Conditional Activator Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of MT2004 in drug induced liver injury (DILI), sponsored by Xi'an Aolitai Pharmaceutical Technology. Started Aug 2023; status: recruiting.
02
Drugs
MT2004
03
Conditions
drug induced liver injury (DILI)
Beyond the preview
Go deeper on NCT06019936.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06019936.